Should preventive antibiotics be used in patients with acute stroke? A systematic review and meta-analysis of randomized controlled trials

PLoS One. 2017 Oct 19;12(10):e0186607. doi: 10.1371/journal.pone.0186607. eCollection 2017.

Abstract

Background: Infection is a common complication in acute stroke. Whether or not preventive antibiotics reduce the risk of infection or even lead to a favorable outcome and reduction of mortality after a stroke still remains equivocal. This review was performed to update the current knowledge on the effect and possible benefits of prophylactic antibiotic therapy in patients with stroke.

Methods: A systematic review and meta-analysis of preventive antibiotics`effect on the incidence of infection, favorable outcome (mRS≤2) and mortality in patients with acute stroke is performed with relevant randomized controlled trials.

Results: Six studies were identified, involving 4125 participants. Compared with the control group, the treated groups were significantly less prone to suffer from early overall infections [RR = 0.52, 95%CI (0.39, 0.70), p<0.0001], early pneumonia [RR = 0.64, 95%CI (0.42, 0.96), p = 0.03] and early urinary tract infections [RR = 0.35, 95%CI (0.25, 0.48), p<0.00001]. However, there was no significant difference in overall mortality [RR = 1.07, 95%CI (0.90, 1.27), p = 0.44], early mortality [RR = 0.99, 95%CI (0.78, 1.26), p = 0.92], late mortality [RR = 1.12, 95%CI (0.94, 1.35), p = 0.21] or favorable outcome [RR = 1.00, 95%CI (0.92, 1.08), p = 0.98].

Conclusion: Although preventive antibiotic treatment did reduce the occurrence of early overall infections, early pneumonia and early urinary tract infection in patients with acute stroke, this advantage was not eventually translated to a favorable outcome and reduction in mortality. Future studies are warranted to identify any subgroup of stroke patients who might benefit from preventive antibiotic treatment.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Acute Disease
  • Anti-Bacterial Agents / therapeutic use*
  • Humans
  • Randomized Controlled Trials as Topic*
  • Stroke / drug therapy*

Substances

  • Anti-Bacterial Agents

Grants and funding

This work was supported by the National Natural Science Foundation of China (81660211), http://www.nsfc.gov.cn/. Shengtao Yao received the funding, and works on Funding acquisition, Investigation, Methodology, Project administration and Validation of current research.